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Background: The goal of this study was to compare treatment outcomes for Federation of Gynecology and
Obstetrics (FIGO) stage IIB cervical carcinoma patients receiving radical surgery followed by adjuvant postoperative
radiotherapy versus radical radiotherapy.
Methods: Medical records of FIGO stage IIB cervical cancer patients treated between July 2008 and December 2011
were retrospectively reviewed. A total of 148 patients underwent radical hysterectomy with pelvic lymph node
dissection followed by adjuvant radiotherapy (surgery-based group). These patients were compared with 290
patients that received radical radiotherapy alone (RT-based group). Recurrence rates, progression-free survival (PFS),
overall survival (OS), local control rates, and treatment-related complications were compared for these two groups.
Results: Similar rates of recurrence (16.89% vs. 12.41%, p = 0.200), PFS (log-rank, p = 0.211), OS (log-rank, p = 0.347),
and local control rates (log-rank, p = 0.668) were observed for the surgery-based group and the RT-based group,
respectively. Moreover, the incidence of acute grade 3–4 gastrointestinal reactions and late grade 3–4 lower limb
lymphedema were significantly higher for the surgery-based group versus the RT-based group. Cox multivariate
analyses found no significant difference in survival outcome between the two groups, and tumor diameter and
histopathology were identified as significant prognostic factors for OS.
Conclusions: Radical radiotherapy was associated with fewer treatment-related complications and achieved
comparable survival outcomes for patients with FIGO stage IIB cervical cancer compared to radical hysterectomy
followed by postoperative radiotherapy.
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Cervical cancer is the most common gynecological cancer
in developing countries, and Federation of Gynecology
and Obstetrics (FIGO) stage IIB cervical cancer is recog-
nized as a locally advanced stage of disease [1]. Currently,
there is no international agreement on how FIGO stage
IIB patients should be treated. The National Comprehen-
sive Cancer Network (NCCN) guidelines recommend
cisplatin-based chemoradiotherapy as a primary treatment* Correspondence: liuzmail@163.com
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stated.for FIGO stage IIB disease [2]. In 2003, the FIGO annual
report indicated 72% of patients with FIGO stage IIB cer-
vical cancer received radical radiotherapy [3]. However,
other guidelines, such as the German Arbeitsgemeinschaft
Gynaekologische Onkologie (AGO) guidelines, recommend
radical hysterectomy plus adjuvant radiotherapy as a feas-
ible approach for the treatment of FIGO stage IIB disease.
There are advantages associated with both primary
surgery and radical radiotherapy. Primary surgery allows
the ovaries to be preserved and avoids early menopause,
and may also decrease vaginal fibrosis compared with
radical radiotherapy [4,5]. Conversely, radiotherapy can
be administered to elderly patients, to patients that have
other diseases present, and to patients with extensived. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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urinary incontinence following surgery [5,6].
In previous observational studies, the 5-year survival
rates for patients with FIGO stage IIB cervical cancer who
were treated with radical surgery plus adjuvant radiother-
apy were reported to range from 64.0% to 85.2%. This
is comparable to the 5-year survival rates of patients
treated with definitive radiotherapy (64.0–81.1%) [1,3,7,8].
However, treatment-related complications, which can sig-
nificantly affect a patient’s quality of life, are a critical con-
sideration when deciding between two treatment modalities
with equivalent survival outcomes [9]. As reported, com-
bined treatment of radical hysterectomy plus adjuvant
radiotherapy is associated with a significantly higher rate
of morbidity compared with surgical treatment alone [10].
Thus, it has been suggested that radical radiotherapy is
beneficial for FIGO stage IIB cervical cancer patients who
require adjuvant radiotherapy following radical hysterec-
tomy [10].
To our knowledge, a comparison of radical surgery
followed by adjuvant postoperative radiotherapy versus
radical radiotherapy for patients with stage IIB cervical
cancer in China has not been reported. Therefore, in
this retrospective study, survival outcomes and treatment-
related complications associated with FIGO stage IIB
cervical cancer patients from the Chinese population who
underwent radical hysterectomy plus postoperative radio-




Data acquisition and the analysis of medical records for 438
patients with stage IIB primary cervical cancer who were
treated at The First Affiliated Hospital of Xi’an Jiaotong
University between July 2008 and December 2011 were ap-
proved by the Ethics Committee of The First Affiliated
Hospital of Xi’an Jiaotong University. The following
inclusion criteria were used for this study: a histological
diagnosis of FIGO stage IIB disease; an absence of prior
treatment; a Karnofsky Performance Status ≥ 80; and the
completion of (a) primary surgery consisting of radical
hysterectomy with pelvic lymphadenectomy combined
with adjuvant radiotherapy, or (b) radical radiotherapy with
concurrent chemotherapy. A pelvic examination in the
absence of anesthesia was conducted, to evaluate patients
according to the FIGO staging system. Baseline data were
available from computed tomography (CT) of the chest
and abdomen, magnetic resonance imaging (MRI) of the
pelvis, and complete blood count and biochemistry panels.
Furthermore, intravenous pyelography, cystoscopy, and
sigmoidoscopy were considered optional. Lymph nodes
measuring 1 cm or greater across their largest diameter
on CT or MRI scans were defined as metastatic nodes.Treatment
All of the patients in the surgery-based group underwent
radical hysterectomy with pelvic lymph node dissection
by laparotomy. Radical hysterectomy included resection
of the uterus along with its attached parametrial soft
tissue and a margin of the upper vagina. The lymphade-
nectomy procedure included a complete bilateral pelvic
lymphadenectomy intending to remove all of the external
iliac, internal iliac, common iliac, obturator, suprainguinal,
and presacral lymph nodes. External beam radiotherapy
(EBRT) was delivered 2–4 weeks later, using a linear accel-
erator of three-dimensional conformal radiation therapy
(3D-CRT). CT-based treatment planning was used for
all patients. According to Radiation Therapy Oncology
Group (RTOG) guidelines [11], the clinical target vol-
ume (CTV) included the common, external, and in-
ternal iliac lymph node regions and the upper 3.0 cm
of the vagina. The superior margin of the external radi-
ation field was located at the abdominal aortic bifurcation,
and the inferior border extended 3.0 cm below the upper
extent of the vagina (defined by the vaginal marker), or to
1.0 cm above the inferior extent of the obturator foramen.
External irradiation was delivered to the whole pelvis
(1.8 Gy or 2 Gy per fraction), with five fractions adminis-
tered per week for a total of 25 fractions and 45–50 Gy.
If common iliac lymph node metastasis was detected, ex-
tended field radiotherapy was additionally administered.
For patients that displayed vaginal invasion close to the
surgical margin (≤ 0.5 cm), they received intracavitary
radiotherapy (ICRT). Patients with one or more pathologic
risk factors (e.g., positive nodes, positive surgical margin)
were administered paclitaxel (135 mg/m2 for the first day)
and cisplatin (25 mg/m2 per day for 3 consecutive days)
(TP regimen) every 21–28 d for four cycles. All patients
received antiemetic drugs and were pretreated with corti-
costeroids, diphenhydramine, and H2 antagonists.
Radical radiotherapy consisted of pelvic EBRT followed
by high dose rate intracavitary brachytherapy (HDR-ICBT).
Pelvic EBRT was administered using a linear accelerator
of 3D-CRT. The pelvic radiation field was the same as that
employed for adjuvant radiotherapy, yet it was extended
inferiorly in cases involving vaginal invasion. External ir-
radiation was delivered to the whole pelvis (1.8–2 Gy
per fraction), with five fractions administered per week
for a total of 25–28 fractions and 50–50.4 Gy. After com-
pleting external irradiation, gynecological examinations
and pelvic MRI were performed to determine the appro-
priate ICBT program and dose. ICBT was performed using
the Fletcher-Suit-Delclos set with a microSelectron HDR
(Nucletron, Veenendaal, Netherlands). Loading was based
on the Manchester radium system. Orthogonal x-rays
were administered after each insertion in order to calcu-
late the dwell times for the prescribed Point A dose. Point
A was defined as 2 cm above the cervical os marker and




Total no. patients 148 290
Median age, y (range) 48 (25–70) 51 (24–88) 0.003
Histopathology 0.456
Squamous cell carcinoma 136 (92.0%) 272 (93.8%)
Non-Squamous cell
carcinoma




Positive 27 (18.24%) 43 (14.83%)




> 40 26 (17.57%) 89 (30.69%)
≤ 40 122 (82.43%) 201 (69.31%)
Pretreatment hemoglobin
level (g/L)
112.12 ± 10.53 113.56 ± 8.41 0.140
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the uterus. Vaginal packing was used to maximize the dis-
tances from the source to the bladder wall and the rectal
wall. The total planned dose to point A for HDR-ICBT
was 24–25 Gy, and it was administered in four or five
fractions. All of the patients in the RT group received one
cycle of cisplatin (25 mg/m2 per day for 3 consecutive
days) combined with 5-fluorouracil (300 g/m2 per day for
5 consecutive days) (PF regimen) during pelvic EBRT as a
radiosensitizing agent. In addition, all patients were ad-
ministered antiemetic drugs prior to chemotherapy.
Patient follow-up
Upon completion of treatment, patients were evaluated
every three months for the first year, every six months
the second through fifth years, and annually thereafter.
Gynecologic examination and supraclavicular lymph node
palpation were performed at each appointment. Chest
x-rays were obtained one year after treatment. Suspected
cases of persistent or recurrent disease were confirmed by
biopsy whenever possible. For these cases, chest CT and
abdomino-pelvic CT or MRI were obtained to detect the
site of failure. Patient follow-up was maintained through
July 31, 2013. The median duration of follow-up was
36 months (range: 12–60 months) for the surgery-based
group and 39 months (range: 16–60 months) for the RT-
based group.
Definition of outcomes and toxicity
Progression-free survival (PFS) was defined as the time
interval between the initial diagnosis (at initial biopsy)
and the detection of recurrence or death from any cause.
Overall survival (OS) was defined as the time from initial
diagnosis until death by cervical cancer. Surviving pa-
tients and patients with an unknown date of death were
censored on the date of last follow-up. Rates of local re-
currence (confined to the pelvis) and distant metastasis
(any site) were also reported for each patient.
Adverse effects that occurred within 90 days from the
start of primary treatment were considered acute com-
plications, and those that occurred 90 days or later from
the start of treatment were considered late complica-
tions. The severity of the complications associated with
radiotherapy or chemotherapy were classified according to
the National Cancer Institute Common Toxicity Criteria
(NCI-CTC v2.0) and the Radiation Therapy Oncology
Group/European Organization for Research and Treatment
of Cancer (RTOG/EORTC) criteria, respectively.
Statistical analysis
Differences between the two treatment groups were
assessed using a χ2 test or Fisher’s exact test for categor-
ical variables. An independent sample t-test was used
for continuous variables. Survival curves were obtainedusing the Kaplan-Meier method and were compared using
nonparametric survival analysis (log-rank test). A P-value
less than 0.05 were considered statistically significant. Multi-
variate analysis was performed using the Cox proportional-
hazard model with a stepwise method (forward selection).
P-values less than 0.05 were used as inclusion criteria and
P-values greater than 0.10 were used as exclusion cri-
teria. Statistical Package for Social Scientists (SPSS, ver-
sion 18.0, IL) was used for all analyses.
Results
Patient characteristics
Of the 438 patients who were eligible for a retrospective
analysis of their cases, 148 were treated with radical
hysterectomy combined with adjuvant chemoradiother-
apy or radiotherapy according to their pathological risk
factors (surgery-based group). In addition, 290 patients
were treated with radical radiotherapy (RT-based group)
(Table 1).
The median ages for the surgery-based and RT-based
groups were 48 years (range, 25–70) and 51 years (range,
24–88), respectively, and this difference was significant
(P = 0.003). Twenty-six (17.57%) patients in the surgery-
based group and 89 (30.69%) patients in the RT-based
group had a maximum tumor diameter > 4 cm, and this
difference was also significant (P = 0.003). In contrast,
pelvic nodal status, histopathology distribution, and pre-
treatment hemoglobin levels did not significantly differ
between the two treatment groups.
In the surgery-based group, 69 patients (46.62%) had
one or more risk factors and received TP regimen for four
cycles. Of these patients, 59 (39.86%) had histologically
positive pelvic nodes, 3 (2.03%) of which had common
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extended field radiotherapy, while 10 patients (6.76%) had
positive vaginal margins and received ICRT. All patients
in the RT-based group were administered one cycle of
PF regimen.
Treatment outcome
The follow-up time for the two groups did not signifi-
cantly differ (P > 0.05). During the follow-up period, 25
(16.89%) patients in the surgery-based group and 36
(12.41%) patients in the RT-based group experienced
tumor recurrence (Table 2). The former included recur-
rence in the pelvis (n = 6, 4.05%), in distant areas outside
of the pelvis (n = 17, 11.49%), and in both pelvic and dis-
tant areas (n = 2, 1.35%). The same regions for the latter
group involved 15 (5.17%), 20 (6.89%), and 1 (0.30%)
cases, respectively. The recurrence rate and pattern of
recurrence did not significantly differ between the two
treatment groups (P = 0.200 and P = 0.224, respectively).
Moreover, at the time of this report, 20 (13.51%) patients
in the surgery-based group and 29 (10.00%) patients in
the RT-based group had died of cervical cancer. One
(0.34%) patient from the RT-based group also died due
to other causes. Mortality rates for the two treatment
groups did not significantly differ (P = 0.324).
Although the RT-based group exhibited slightly higher
PFS rates and OS rates (Figure 1), the differences were not
statistically significant (log-rank; P = 0.211 and P = 0.347,
respectively). The 5-year PFS rates were 80.8% for the
surgery-based group and 86.0% for the RT-based group,
while the estimated 5-year OS rates were 84.7% and 86.8%,
respectively. The pelvic recurrence rate was similar for
the patients in the surgery-based group and those in the
RT-based group (Figure 2, log-rank, P = 0.668).
After controlling for other variables in the multivariate
analysis, no significant difference in survival outcome was
detected between the two treatment groups (Table 3). How-
ever, multivariate analysis did demonstrate that histologyTable 2 Treatment outcome
Characteristic Surgery-based group RT-based group P-value
Total no. patients 148 290
Patients with
recurrence, N (%)
25 (16.89%) 36 (12.41%) 0.200
Site of recurrence 0.224
Pelvis 6 (4.05%) 15 (5.17%)
Pelvis plus distant 2 (1.35%) 1 (0.30%)
Distant 17 (11.49%) 20 (6.89%)
Total deaths 0.324
N (%) 20 (13.51%) 30 (10.34%)
Disease 20 (13.51%) 29 (10.0%)
Other 0 (0%) 1 (0.34%)and tumor diameter were significant prognostic factors
for OS.
Adverse effects
No treatment-related deaths were reported for the co-
hort examined. Surgery-related complications were clas-
sified according to the Clavien-Dindo guidelines [12].
For 148 patients in the surgery-based group, 90 (60.81%)
did not experience surgery-related complications. How-
ever, grade I complications were reported for 5 (3.38%)
patients, and these mainly included fever and pain. Grade
II complications were reported for 47 (31.76%) patients,
and these included wound infections (n = 5) and bladder
dysfunction (n = 42). Furthermore, 2 (1.35%) patients had
large infected lymphocysts (grade IIIa) and 4 (2.70%) pa-
tient suffered a ureteral fistula (grade IIIb). All of these
complications recovered within four weeks.
As shown in Table 4, the frequencies of acute grade
3–4 neutropenia and anemia were similar for the two
reatment groups (P = 0.610 and P = 0.067, respectively).
For the 148 patients in the surgery-based group, 15
(10.14%) patients suffered grade 3–4 acute gastrointes-
tinal reactions, with 3 (2.03%) patients developing small
bowel obstruction (SBO) and 12 (8.11%) patients hav-
ing diarrhea, both of which were treated conservatively.
Among the 290 patients treated with radical radiother-
apy, 13 (4.48%) patients suffered diarrhea and were treated
conservatively. Overall, the incidence of acute grade
3–4 gastrointestinal reactions was significantly higher
for the surgery-based group compared to the RT-based
group (P = 0.036). It is possible that this was due to inflam-
mation in the pelvis, intestinal wall edema, and gastro-
intestinal irritation that developed as a result of the
surgery performed.
Radiation enteritis, cystitis, and lower limb edema were
the most common late stage toxicities reported. In the
surgery-based group, 11 (7.43%) patients developed chronic
radiation intestinal injury, with 2 (1.35%) patients de-
veloping SBO (one was treated with enterolysis and
one was treated conservatively) and 9 (6.08%) patients
experiencing proctosigmoiditis. The latter was allevi-
ated by adjusting the patients’ diets and administering
Chinese medicine. The same treatment was used for
the 12 (4.14%) in the RT-based group that also devel-
oped chronic proctosigmoiditis. In addition, chronic radi-
ation cystitis was reported for 6 (10.81%) patients in the
surgery-based group and 7 (3.45%) patients in the RT-
based group. When the two groups were compared, the
frequencies of late stage grade 3–4 radiation intestinal
injury and cystitis were similar (P = 0.144 and P = 0.378,
respectively). Ten (6.76%) patients in the surgery-based
group and 6 (2.07%) patients in the RT-based group
suffered severe lower limb edema, respectively, and this
difference was significant (P = 0.017) (Table 4). Lymph
Figure 1 Kaplan-Meier PFS (A) and OS survival (B) curves for the surgery-based group and RT-based group. Both rates were similar for
the two groups (log-rank, P = 0.211 and P = 0.347, respectively).
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result of the lymph node dissections that were performed.
Discussion
In the present study, 438 patients with FIGO stage IIB
cervical cancer treated with radical surgery plus adjuvant
radiotherapy (n =148) or radical radiotherapy (n = 290)
were retrospectively analyzed. OS and PFS did not sig-
nificantly differ for the two treatment groups, although
the RT-based group showed slightly higher PFS and OS
rates (log-rank, P = 0.211 and P = 0.347, respectively).Figure 2 Cumulative pelvic recurrence rates were calculated for patie
rates were similar for the two groups (log-rank, P = 0.668).Previously, Yamashita et al. [7] retrospectively compared
the survival of stage IIB patients who underwent radical
hysterectomy followed by adjuvant radiotherapy versus
those who underwent radiotherapy. The reported 5-year
cause-specific survival rates for the two groups were
81.1% and 81.2%, respectively. Furthermore, the differ-
ence was not statistically significant. Ohara et al. [8] re-
ported 5-year cause-specific survival rates of 70.5% and
85.2% for the radiotherapy group and the radical hyster-
ectomy group of FIGO stage IIB cervical cancer pa-
tients, respectively, while Takahiro et al. [1] reportednts in the surgery-based group versus the RT-based group. These
Table 3 Multivariate analysis for survival outcome
Characteristic PFS OS
HR (95% CI) P-value HR (95% CI) P-value
Age, y (> 45 vs. ≤ 45) 0.774 (0.454–1.318) 0.345 0.986 (0.542–1.796) 0.964
Maximum tumor diameter 1.379 0.264 2.023 0.021
(> 40 mm vs. ≤ 40 mm) (0.785–2.422) (1.114–3.672)
Histology 0.832 0.695 0.440 0.045
(SCC vs. non-SCC) (0.331–2.087) (0.197–0.982)
Pre-RT hemoglobin (g/L) 0.654 0.100 0.788 0.406
(> 110 vs. ≤ 110) (0.394–1.084) (0.449–1.383)
Treatment
Surgery + adjuvant RT 1.441 0.170 1.466 0.195
vs. radical RT (0.856–2.428) (0.822–2.615)
PFS: progression-free survival; OS: overall survival; HR: hazard ratio, 95% CI: 95% confidence interval, SCC: squamous cell carcinoma, RT: radiotherapy.
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tomy group and a radiotherapy group. Therefore, the
results of the present study are consistent with previous
findings [1,8,11,13].
In general, the complications associated with radical
hysterectomy with adjuvant radiation therapy or radical
radiotherapy can include proctitis, cystitis, lower limb
lymphedema, urinary and rectal fistula, rectal stricture,
and bladder dysfunction [14,15]. In the current study, ra-
diation enteritis, cystitis and lower limb edema were the
most common late stage toxicities reported. These condi-
tions typically developed in the first two years following
treatment, and were largely alleviated by diet adjust-
ments and Chinese medicine. However, treatment of
lower limb edema remains a challenge. The frequency






Total no. patients 148 290
Grade 3–4 acute toxicity
Neutropenia 50 (33.8%) 91 (31.4%) 0.610
Anemia 12 (8.11%) 41 (14.1%) 0.067
Gastrointestinal reactions 15 (10.1%) 13 (4.48%) 0.036
Small bowel obstruction 3 (2.03%) 0 (0.00%)
Diarrhea 12 (8.11%) 13 (4.48%)




11 (7.43%) 12 (4.14%) 0.144
Small bowel obstruction 2 (1.35%) 0 (0.00%)
Proctosigmoiditis 9 (6.08%) 12 (4.14%)
Chronic radiation cystitis 6 (4.05%) 7 (2.41%) 0.378
Lower limb lymphedema 10 (6.76%) 6 (2.07%) 0.017group was significantly higher than that observed for the
RT-based group. It is important that patients are informed
of the lifelong risks of these complications prior to sur-
gery, since these adverse reactions can lead to a serious
decline in patient quality of life. Moreover, careful post-
treatment follow-up and timely treatment of complica-
tions can help avoid more serious adverse complications
and reduce the need for major interventions.
Considering the relatively high incidence of severe compli-
cations observed in both treatment groups in the current
study, further efforts need to be made to reduce the inci-
dences of these complications. One possibility is the use of
more conformal dose distributions with intensity-modulated
radiation therapy (IMRT) [16]. There have been a consid-
erable number of studies that have demonstrated that
IMRT improves dose distributions and is associated with
reduced rates of toxicities, while providing comparable
clinical outcomes [17,18]. It will be important for add-
itional clinical trials of IMRT to be conducted to evaluate
adjuvant and radical radiotherapy for stage IIB cervical
disease.
Patients with FIGO stage IIB cervical cancer usually
exhibit high risk pathological factors following radical
hysterectomy such as positive pelvic nodes, parametrial
invasion, or a positive surgical margin. For these individ-
uals, postoperative adjuvant radiotherapy is inevitable.
Consequently, opting for radical radiotherapy instead of
radical surgery, especially for patients exhibiting risk fac-
tors for the development of severe late stage toxicities
[19,20], may provide a better quality of life.
In recent literature, the use of neoadjuvant chemother-
apy (NACT) followed by radical surgery for patients with
FIGO stage IIB cervical cancer has shown an increas-
ing trend. Both Gadducci et al. [21] and Minig et al. [22]
found that neoadjuvant chemotherapy followed by radical
surgery was also an effective therapeutic option for pa-
tients with FIGO stage IIB cervical cancer. Moreover, this
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pared to radical radiotherapy. At present, a number of
clinical trials involving the application of NACT for
patients with FIGO stage IIB cervical cancer are ongoing.
When these results are released, the advantages and
disadvantages of NACT for this population can be further
examined.
In the current study, tumor diameter and histopath-
ology were identified as significant prognostic factors
for OS (Table 3). These results are consistent with those
of previous studies where tumor size [23,24] and non-
squamous histological type [24-26] were identified as
prognostic factors for the survival of FIGO stage IIB cer-
vical cancer patients. Thus, the development of new treat-
ment strategies for patients with known risk factors for
survival is urgently needed. For this purpose, novel treat-
ments that include the use of new cytotoxic and/or
biologic agents as radiosensitizers, or the addition of
consolidation chemotherapy following postoperative adju-
vant radiotherapy or definitive radiotherapy, should be
investigated in future clinical trials [7].
Regarding the limitations of the present study, its
retrospective nature is a key aspect. Potential confound-
ing biases may also have been missed in the analyses
performed, such as the selection bias introduced by phy-
sicians in determining which patients should be consid-
ered for radical surgery plus adjuvant radiotherapy versus
radical radiotherapy alone. Patients in the surgery-based
group were significantly younger and typically had tumors
with smaller diameters, indicating that a greater number
of patients with favorable prognoses were allocated to the
surgery-based group. There are several possible explana-
tions for this. Surgery is preferred for the treatment of
younger cervical cancer patients. In addition, surgeons
prefer surgical treatment for patients with smaller tumors
since the surgery is relatively straightforward. Another
limitation of the present study is the imbalanced number
of patients in each treatment group and the short follow-
up period. A prospective, randomized controlled study
would eliminate these biases.
Conclusion
In conclusion, radical radiotherapy was found to be a
safer treatment approach compared to radical hysterec-
tomy followed by postoperative radiotherapy for FIGO
stage IIB cervical cancer. Specifically, radical radiother-
apy was associated with fewer treatment-related compli-
cations and achieved a comparable survival outcome. To
confirm the superiority of radical radiotherapy for FIGO
stage IIB cervical cancer, survival outcome, frequency of
treatment-related complications, and patient quality of
life following radical radiotherapy versus radical surgery
followed by adjuvant postoperative radiotherapy needs
to be evaluated in a randomized controlled trial.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images.
Abbreviations
FIGO: Federation of gynecology and obstetrics; PFS: Progression-free survival;
OS: Overall survival; NCCN: National comprehensive cancer network;
CT: Computed tomography; MRI: Magnetic resonance imaging;
EBRT: External beam radiotherapy; 3D-CRT: Three-dimensional conformal
radiation therapy; RTOG: Radiation therapy oncology group; CTV: Clinical
target volume; ICRT: Intracavitary radiotherapy; HDR-ICBT: High dose rate
intracavitary brachytherapy; RIAISs: Radiation-induced acute intestinal
symptoms; IMRT: Intensity-modulated radiation therapy; NACT: Neoadjuvant
chemotherapy.
Competing interest
The authors declare that they have no competing interests. This paper has
not been published previously. This study will not be published elsewhere in
the same form, in English or in any other language, without consent of the
publisher.
Authors’ contributions
YC guarantees the integrity of the entire study and drafted the manuscript.
JW and YG collected medical records. TW and YY performed statistical
analyses. YG, JG, and SG searched and arranged the references. YW and XZ
modified the manuscript. ZL conceived the study, participated in its design
and coordination, and completed the final proofreading of the manuscript.
All authors have read and approve the final manuscript.
Acknowledgements
This study was financially supported by the National Natural Science
Foundation of China (No. 81071838) and the Department of Health Key
Program of Shaanxi Province (No.2010A02). We are grateful to Hongwei
Chen, Fan Shi, Yingbing Zhang, and Beina Hui for their support in data
acquisition. We also thank the patients who participated in this study.
Author details
1The Department of Radiotherapy Oncology of the 1st Affiliated Hospital,
Xi’an Jiao Tong University, Xi’an 710061, China. 2The Department of
Gynecology of the 1st Affiliated Hospital, Xi’an Jiao Tong University, Xi’an
710061, China. 3Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei
442000, China.
Received: 1 November 2013 Accepted: 28 January 2014
Published: 4 February 2014
References
1. Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S: Radical hysterectomy for
FIGO stage IIB cervical cancer: clinicopathological characteristics and
prognostic evaluation. Gynecol Oncol 2009, 114:69–148.
2. NCCN: Practice Guidelines in Oncology. 2013. http://www.nccn.org/
professionals/physician_gls/f_guidelines.asp.
3. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP,
Ngan HY, Pecorelli S: Carcinoma of the cervix uteri. Int J Gynaecol Obstet
2003, 83(Suppl 1):41–78.
4. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, Favini G, Ferri L,
Mangioni C: Randomised study of radical surgery versus radiotherapy for
stage Ib–IIa cervical cancer. Lancet 1997, 350:535–540.
5. Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P: Early-stage
cervical cancer: is surgery better than radiotherapy? Expert Rev Anticancer
Ther 2010, 10:451–460.
6. Suprasert P, Srisomboon J, Kasamatsu T: Radical hysterectomy for stage IIB
cervical cancer: a review. Int J Gynecol Cancer 2005, 15:995–1001.
7. Yamashita H, Nakagawa K, Tago M, Shiraishi K, Nakamura N, Ohtomo K,
Oda K, Nakagawa S, Yasugi T, Taketani Y: Comparison between
conventional surgery and radiotherapy for FIGO stage I–II cervical
carcinoma: a retrospective Japanese study. Gynecol Oncol 2005,
97:834–839.
Chai et al. BMC Cancer 2014, 14:63 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/638. Ohara K, Sugahara S, Kagei K, Hata M, Igaki H, Tokuuye K, Akine Y:
Retrospective comparison of clinical outcome between radiotherapy
alone and surgery plus postoperative radiotherapy in the treatment
of stages IB–IIB cervical squamous cell carcinoma. Radiat Med 2004,
22:42–48.
9. Mabuchi S, Okazawa M, Isohashi F, Matsuo K, Ohta Y, Suzuki O, Yoshioka Y,
Enomoto T, Kamiura S, Kimura T: Radical hysterectomy with adjuvant
radiotherapy versus definitive radiotherapy alone for FIGO stage IIB
cervical cancer. Gynecol Oncol 2011, 123(2):241–247.
10. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI,
Zaino RJ: A phase III randomized trial of postoperative pelvic irradiation
in Stage IB cervical carcinoma with poor prognostic features: follow-up
of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006,
65(1):169–176.
11. Small W Jr, Mell LK, Anderson P, Creutzberg C, De Los SJ, Gaffney D,
Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ:
Consensus guidelines for delineation of clinical target volume for
Intensity-Modulated pelvic radiotherapy in postoperative treatment of
endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2008,
71(2):428–434.
12. Oranusi CK, Nwofor A, Oranusi IO: Complication rates of open transvesical
prostatectomy according to the Clavien–Dindo classification system.
Niger J Clin Pract 2012, 15(1):34–37.
13. Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE: Patterns of treatment
failure following radiotherapy with combination chemotherapy for
patients with high-riskstage IIB cervical carcinoma. Int J Clin Oncol 2004,
9(2):120–124.
14. Einstein MH, Rash JK, Chappell RJ, Swietlik JM, Hollenberg JP, Connor JP:
Quality of life in cervical cancer survivors: patient and provider
perspectives on common complications of cervical cancer and
treatment. Gynecol Oncol 2012, 125(1):163–167.
15. Hsu WC, Chung NN, Chen YC, Ting LL, Wang PM, Hsieh PC, Chan SC:
Comparison of surgery or radiotherapy on complications and quality of
life in patients with the stage IB and IIA uterine cervical cancer.
Gynecol Oncol 2009, 115(1):41–45.
16. Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, Hasan Y,
Roeske JC, Mundt AJ, Mell LK: Clinical outcomes of intensity-modulated
pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol
Biol Phys 2011, 80:1436–1445.
17. Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V,
Barakat RR, Alektiar KM: Postoperative pelvic intensity-modulated
radiotherapy and concurrent chemotherapy in intermediate- and
high-risk cervical cancer. Gynecol Oncol 2013, 128(2):288–293.
18. Du XL, Tao J, Sheng XG, Lu CH, Yu H, Wang C, Song QQ, Li QS, Pan CX:
Intensity-modulated radiation therapy for advanced cervical cancer:
a comparison of dosimetric and clinical outcomes with conventional
radiotherapy. Gynecol Oncol 2012, 125(1):151–157.
19. Chen SW, Liang JA, Yang SN, Liu RT, Lin FJ: The prediction of late rectal
complications following the treatment of uterine cervical cancer by
high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2000,
47(4):955–961.
20. Gondi V, Bentzen SM, Sklenar KL, Dunn EF, Petereit DG, Tannehill SP,
Straub M, Bradley KA: Severe late toxicities following concomitant
chemoradiotherapy compared to radiotherapy alone in cervical cancer:
an inter-era analysis. Int J Radiat Oncol Biol Phys 2012, 84(4):973–982.
21. Gadducci A, Sartori E, Maggino T, Zola P, Cosio S, Zizioli V, Lapresa M,
Piovano E, Landoni F: Pathological response on surgical samples is an
independent prognostic variable for patients with Stage Ib2-IIb cervical
cancer treated with neoadjuvant chemotherapy and radical hysterectomy:
An Italian multicenterretrospective study (CTF Study). Gynecol Oncol 2013,
3. pii: S0090-8258(13)01203-1.
22. Minig L, Colombo N, Zanagnolo V, Landoni F, Bocciolone L, Cárdenas-
Rebollo JM, Iodice S, Maggioni A: Platinum-based neoadjuvant
chemotherapy followed by radical surgery for cervical carcinoma
international federation of gynecology and obstetrics stage IB2-IIB.
Int J Gynecol Cancer 2013 [Epub ahead of print].
23. Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B: Tumor size is of
prognostic value in surgically treated FIGO stage II cervical cancer.
Gynecol Oncol 2007, 107:310–315.
24. Reig A, Membrive I, Foro P, Sanz X, Rodríguez N, Lozano J, Lacruz M, Quera J,
Fernández-Velilla E, Algara M: Long-term results and prognostic factors ofpatients with cervical carcinoma treated with concurrent
chemoradiotherapy. Clin Transl Oncol 2011, 13(7):504–508.
25. Xie XZ, Song K, Cui B, Jiang J, Zhang YZ, Wang B, Yang XS, Kong BH:
Clinical and pathological factors related to the prognosis of Chinese
patients with stage Ib to IIb cervical cancer. Asian Pac J Cancer Prev 2012,
13(11):5505–5510.
26. Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL,
Wright JD: Prognostic significance of adenocarcinoma histology in
women with cervical cancer. Gynecol Oncol 2012, 125(2):287–291.
doi:10.1186/1471-2407-14-63
Cite this article as: Chai et al.: Radical hysterectomy with adjuvant
radiotherapy versus radical radiotherapy for FIGO stage IIB cervical
cancer. BMC Cancer 2014 14:63.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
